Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 101Breast 9Tumor-Agnostic 3Head & Neck 3Thoracic 2Other solid neoplasm 2Gynecologic 2Gastrointestinal 2Dermatologic 2Lymphoid 1

Conditions

Solid Tumours 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1Mesothelioma 1Melanoma 1Liver Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Camurati-Engelmann Syndrome 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 26Pemetrexed 26Cisplatin 25Nivolumab 22Carboplatin 16Paclitaxel 14Gemcitabine 12Ipilimumab 11tislelizumab 8durvalumab 8Ramucirumab 8Docetaxel 8talazoparib 7Fluorouracil 7Radiotherapy 6Capecitabine 6tremelimumab 5cobimetinib 5atezolizumab 5adavosertib 5Radiosurgery 5Cyclophosphamide 5Bevacizumab 5olaparib 4avelumab 4Temozolomide 4Sunitinib 4Specimen Handling 4Platinum 4PM 01183 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × enzalutamide × Other solid neoplasm × Clear all
NCT03685591 2024-06-26

PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors

Pfizer

Phase 1 Terminated
49 enrolled 33 charts
BreastDermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Adenocarcinoma, Breast Neoplasms, Carcinoma, Renal Cell, Camurati-Engelmann Syndrome, Liver Neoplasms, Melanoma, Mesothelioma, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Neoplasms, Squamous Cell

NCT03150056 2022-08-10

Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer

GlaxoSmithKline

Phase 1 Terminated
73 enrolled 34 charts
Other solid neoplasm

Solid Tumours

Data powered by HemOnc (CC BY 4.0) Colophon âš¡